/////////// Investor Conference Call FY/Q4 2022 Results February 28th, 2023 Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include ...

Bayer AG (OTCPK:BAYZF) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Oliver Maier - Head, IR Werner Baumann - Chairman, CEO & Chief Sustainability Officer Wolfgang Nickl - CFO Heiko Schipper - President, Consumer Health Division Rodrigo Santos - President, Crop Science Division Stefan Oelrich - Head, Pharmaceuticals Division Conference Call Participants Michael Leuchten - UBS Richard Vosser - JPMorgan Chase & Co. Peter Verdult - Citi Vincent Andrews - Morgan Stanley Sachi ...

Quarterly Statement Third Quarter of 2022 Bayer with continued strong performance // Group sales at €11.3 billion (Fx & p adj. + 5.7%) // EBITDA before special items rises significantly to €2.5 billion (+ 17.3%) // Crop Science achieves strong sales gains; sales also up at Pharmaceuticals and Consumer Health // All divisions report significant increase in earnings // Core earnings per share at €1.13 (+ 7.6%) // Net income at €0.5 billion // Free cash flow at €1.7 billion // Major progress in Pharmaceuticals ...

Bayer Aktiengesellschaft (OTCPK:BAYZF) Q2 2022 Results Conference Call August 4, 2022 9:00 AM ET Company Participants Oliver Maier - Head, IR Werner Baumann - CEO Wolfgang Nickl - CFO Rodrigo Santos - Head, Crop Science Stefan Oelrich - Head, Pharmaceuticals Heiko Schipper - Head, Consumer Health Conference Call Participants James Quigley - Morgan Stanley Michael Leuchten - UBS Peter Verdult - Citigroup Vincent Andrews - Morgan Stanley Sachin Jain - Bank of America Richard Vosser - JPMorgan Tony Jones - Red ...

Q2 2022 Financial Performance - Sales increased by 18% to €12819 million[14], with a currency and portfolio adjusted (cpa) increase of 10%[14] - EBITDA before special items increased by 30% to €3349 million[14], with a foreign exchange tailwind of €300 million[14] - Core EPS from continuing operations increased by 20% to €193[14] - Free cash flow decreased by 1% to €1140 million[14] Crop Science Division - Sales increased by 29% to €6461 million[19], with a cpa increase of 17%[19] driven by price (+20%)[19] and currency (+12%)[19], offset by volume (-2%)[19] and portfolio (0%)[19] - EBITDA before special items increased by 72% to €1749 million[19] - Herbicides sales increased by 51% due to favorable market dynamics[21] - Corn S&T sales increased by 10% due to new hybrid launches[21] Pharmaceuticals Division - Sales increased by 7% to €4818 million[26], with a cpa increase of 2%[26] driven by volume (+2%)[26] and currency (+5%)[26], offset by price (0%)[26] and portfolio (0%)[26] - EBITDA before special items increased by 5% to €1478 million[26] - Eylea sales increased by 12% across all regions[26] - Xarelto sales decreased by 6% due to procurement changes in China and loss of exclusivity in Brazil[26] Consumer Health Division - Sales increased by 16% to €1496 million[28], with a cpa increase of 7%[28] driven by volume (+3%)[28], price (+4%)[28], currency (+9%)[28] and portfolio (+1%)[28] - EBITDA before special items increased by 19% to €330 million[28] - Allergy & Cold product sales increased by 17% due to higher cold incidences[28] FY 2022 Outlook - Sales growth for Crop Science is expected to be ~13% (cpa)[31], with an EBITDA margin of ~27%[31] - Sales growth for Consumer Health is expected to be 6%-7% (cpa)[31], with an EBITDA margin of 22%-23%[31] - Group sales are projected to be €47-48 billion[36], with an EBITDA margin of 26-27%[36] and core EPS of ~€730[36]

Science for a Better Life A Global Leader in Health & Nutrition /////////// BMO Global Farm to Market Conference May 2022 / Bayer AG 1 /// Bayer AG /// BMO Global Farm to Market Conference /// May 2022 Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual futur ...

/////////// Investor Conference Call Q1 2022 Results May 10th, 2022 Werner Baumann, CEO Wolfgang Nickl, CFO Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates gi ...

Bayer Aktiengesellschaft (OTCPK:BAYZF) Q1 2022 Results Conference Call May 10, 2022 8:00 AM ET Company Participants Oliver Maier - Head, IR Werner Baumann - CEO Wolfgang Nickl - CFO Rodrigo Santos - President, the Crop Science Division Stefan Oelrich - Head, the Pharmaceuticals Division Conference Call Participants Vincent Andrews - Morgan Stanley Pete Verdult - Citigroup Sachin Jain - Bank of America Michael Leuchten - UBS James Quigley - Morgan Stanley Keyur Parekh - Goldman Sachs Falko Friedrich - Deutsc ...

/////////// Investor Conference Call FY/Q4 2021 Results March 1, 2022 Werner Baumann, CEO Wolfgang Nickl, CFO Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates ...

Bayer AG (OTCPK:BAYZF) Q4 2021 Earnings Conference Call March 1, 2022 8:00 AM ET Company Participants Oliver Maier - Head, IR Werner Baumann - Chairman, CEO & Chief Sustainability Officer Rodrigo Santos - President, the Crop Science Division Wolfgang Nickl - CFO Stefan Oelrich - Head, the Pharmaceuticals Division Heiko Schipper - President, the Consumer Health Division Conference Call Participants Vincent Andrews - Morgan Stanley Peter Verdult - Citigroup Michael Leuchten - UBS Sachin Jain - Bank of America ...